Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 18 (PMID 42035021) is a title-only deferred record with no abstract, study design, or findings. It is excluded from scoring and ranking pending full retrieval in the next run.
Article 1 — ZUMA-2 Five-Year Follow-Up: Brexu-cel in R/R MCL
PMID: 42036693 | 🟠 Novel Treatment | Triage Score: 9
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Five-year OS/DOR data for the only approved CAR-T in MCL is a meaningful extension of knowledge — not a new mechanism, but long-term durability data for CAR-T in MCL has been uncertain; confirms sustained benefit beyond 4 years |
| Clinical Relevance | 9 | Directly practice-shaping: confirms durable CR and OS at 5 years in a disease where historical median OS post-relapse was <2 years; strengthens case for brexu-cel as standard of care in eligible R/R MCL patients |
| Population Reach | 5 | MCL is rare (~1/100,000; ~5,000 new cases/year in US); scored relative to unmet need in R/R MCL, which is substantial — this reaches most R/R MCL patients eligible for CART |
| Implementation Speed | 8 | Brexu-cel (Tecartus) is already FDA/EMA approved; these data reinforce existing use, may expand second-line consideration and inform shared decision-making immediately |
| Evidence Strength | 7 | Pivotal trial long-term cohort extension (n=68); single-arm, no comparator, but this is expected for R/R MCL; median follow-up 67.8 months is exceptional for CAR-T; abstract-only limits full assessment |
Key quantitative result: Median OS 46.5 months (complete responders: 60.2 months); median DOR 36.5 months; no T-cell malignancies at 5 years.
External validation: No independent external replication; ZUMA-2 remains the pivotal single-arm trial. Corroborated by real-world registry data (CIBMTR) published separately.
Main limitation: Single-arm trial, no randomized comparator; n=68 is small even for a rare disease setting; abstract-only access limits full toxicity and subgroup assessment.
Equity implications: CAR-T access heavily concentrated in academic medical centers; patients in rural areas, lower SES, and underserved racial/ethnic groups face significant access barriers. Manufacturing capacity and cost (~$400K+) remain major inequity drivers.
Evidence Maturity: ✅ Confirmed Validated — supports continued and potentially expanded clinical use.
Article 2 — TMB Predicts PD-1 Blockade Response in HNSCC: Meta-Analysis
PMID: 42036313 | 🟢 Near-Term Implementable | Triage Score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | TMB as ICI predictor is established in other cancers; this meta-analysis adds HNSCC-specific thresholds and bTMB vs. tTMB calibration — incremental but clinically meaningful |
| Clinical Relevance | 8 | Directly addresses a major clinical gap: which HNSCC patients benefit from PD-1 blockade? Establishes bTMB ≥16 mut/Mb and tTMB ~10 mut/Mb thresholds with actionable ORR/OS/PFS effect sizes |
| Population Reach | 6 | HNSCC is the 6th most common cancer globally (~900,000 new cases/year); not all are ICI candidates, but meaningful proportion are; liquid biopsy implementation could scale widely |
| Implementation Speed | 7 | TMB testing infrastructure increasingly available; Foundation One CDx tTMB already FDA-cleared for some indications; bTMB thresholds need prospective validation but framework is near-implementable |
| Evidence Strength | 8 | Meta-analysis of 17 cohorts, n=1,472; I²=0% for ORR (negligible heterogeneity); strong pooled effect sizes (OR=2.80, HR=0.58); limited by abstract-only access and likely heterogeneous treatment lines across cohorts |
Key quantitative result: ORR OR=2.80; OS HR=0.58 (42% mortality reduction); PFS HR=0.66. tTMB threshold ~10 mut/Mb; bTMB threshold ≥16 mut/Mb.
External validation: Meta-analytic design inherently aggregates across cohorts; no prospective validation study identified in this batch.
Main limitation: Retrospective cohort aggregation; ICI regimens and treatment lines likely heterogeneous across included studies; bTMB threshold not yet prospectively validated in HNSCC.
Equity implications: Tissue biopsy (tTMB) more established but invasive; bTMB via liquid biopsy could democratize testing if threshold validated — important for patients with inaccessible tumor locations. Higher bTMB threshold (≥16) may reduce sensitivity and disadvantage patients with insufficient ctDNA shedding.
Evidence Maturity: ✅ Confirmed Validated with caveat that prospective bTMB threshold confirmation is still needed.
Article 3 — Allostatic Load and Colorectal Cancer Risk in Asian Cohort
PMID: 42033061 | 🟡 Underserved Population | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Allostatic load–cancer associations exist in Western literature; extension to multiethnic Asian populations and CRC specifically is genuinely novel; the 53% elevated risk effect size is larger than most prior Western estimates |
| Clinical Relevance | 5 | Allostatic load is a composite measure not yet integrated into clinical CRC risk tools; actionability is currently indirect (population screening, lifestyle intervention) rather than direct clinical decision support |
| Population Reach | 8 | Asian populations represent >4 billion people globally; CRC is common across all ethnic groups; allostatic load is modifiable — broad prevention relevance |
| Implementation Speed | 5 | Allostatic load scoring requires multiple biomarkers; not currently embedded in routine clinical workflows; would require guideline integration and tool validation before widespread uptake |
| Evidence Strength | 7 | Large prospective cohort (n=30,443); registry-linked outcomes; 7.2-year follow-up; multivariable adjustment; full text available. Limitation: only 162 CRC cases (0.5% event rate) limits statistical power for subgroup analyses |
Key quantitative result: aHR=1.53 (95% CI 1.10–2.14) for high allostatic load (score ≥3) vs. low.
External validation: Extends and confirms prior Western cohort findings to Asian populations — indirect cross-population replication.
Main limitation: Low event count (162 cases) despite large cohort limits subgroup statistical power; allostatic load components may have different cultural/physiological thresholds across ethnic groups.
Equity implications: Directly addresses an underrepresented population in cancer risk research; findings could inform targeted CRC prevention strategies for Chinese, Malay, and Indian subpopulations. Physiological stress burden disproportionately affects lower-SES groups.
Evidence Maturity: ✅ Confirmed Validated.
Article 4 — SES Disparities in Multiple Myeloma Survival, Australia
PMID: 42032835 | 🟡 Underserved Population | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | SES–cancer survival disparities are well-documented broadly; this adds MM-specific Australian data with strong mediation evidence pointing to ASCT access as the key driver — the mediation analysis is the novel contribution |
| Clinical Relevance | 6 | Actionable for health policy: ASCT access is the mediating mechanism, giving a specific policy lever. Less directly actionable for individual clinical decisions |
| Population Reach | 5 | MM is uncommon (~7/100,000); but findings generalize conceptually to any health system with treatment access disparities; ~34,000 new MM cases/year in US alone |
| Implementation Speed | 6 | Policy interventions (equitable ASCT referral pathways, regional treatment programs) are feasible in Australia's public health system; no new technology required |
| Evidence Strength | 7 | Large registry cohort (n=6,030); 12-year period (2008–2019); multivariable analysis with mediation; population-based design. Limitation: abstract-only, retrospective, Australia-specific |
Key quantitative result: 5-year cumulative mortality 42% (low SES) vs. 34% (high SES); 20–27% higher excess mortality risk in low SES; mediated primarily by ASCT access and hospital type.
External validation: Consistent with prior US and European disparities literature in MM.
Main limitation: Retrospective registry design; confounding by comorbidities, frailty, and patient preferences not fully captured; Australia-specific findings may not generalize directly.
Equity implications: Core equity finding — this paper IS the equity evidence. Low-SES patients denied equivalent survival benefit due to structural treatment access barriers.
Evidence Maturity: ✅ Confirmed Validated.
Article 5 — Metabolic Syndrome Trajectory and Cardiometabolic Multimorbidity, CHARLS
PMID: 42036722 | ⬜ Standard | Triage Score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | K-means trajectory clustering applied to MetSyn exposure is a methodological novelty; but MetSyn–cardiometabolic disease associations are well-established; cumulative burden framing is incremental |
| Clinical Relevance | 5 | Physical activity moderation finding is actionable; but composite trajectory tools not yet validated for clinical implementation; indirect relevance to GLP-1/SGLT2 management decisions |
| Population Reach | 7 | Chinese adults represent ~1.4B people; cardiometabolic multimorbidity is a leading global health burden; findings relevant beyond China |
| Implementation Speed | 4 | Requires longitudinal MetSyn scoring and trajectory analysis — not easily implemented in point-of-care settings without infrastructure development |
| Evidence Strength | 5 | Longitudinal CHARLS national cohort; K-means clustering is validated methodology; however, sample size not reported in abstract, and medium classification confidence limits scoring |
Key quantitative result: Specific HRs/ORs not available in abstract; direction and significance of associations stated.
Main limitation: Sample size not reported; abstract-only; K-means cluster labeling is post-hoc and subject to interpretation.
Equity implications: Findings relevant to aging Chinese rural populations where healthcare access is limited; lifestyle interventions feasible but infrastructure-dependent.
Evidence Maturity: ✅ Confirmed Validated (design quality), though quantitative effect sizes need full-text review.
Article 6 — LDL-C + Chinese Visceral Adiposity Index for Cardiometabolic Risk
PMID: 42036685 | ⬜ Standard | Triage Score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Combining LDL-C with CVAI is a pragmatic incremental innovation; CVAI itself is relatively novel for Asian body composition; the composite risk tool adds marginal novelty |
| Clinical Relevance | 6 | Both LDL-C and waist/BMI measures are already collected in routine care; a validated composite score could be implemented with no new testing required — high feasibility |
| Population Reach | 7 | Chinese-specific population but applicable framework for Asian populations broadly; cardiometabolic disease is globally dominant burden |
| Implementation Speed | 6 | Composite score uses existing clinical data; potential for rapid integration into electronic health records in Asian healthcare systems |
| Evidence Strength | 5 | Prospective national cohort design is strong; but sample size not reported; abstract-only; medium classification confidence |
Key quantitative result: Improved risk stratification "beyond individual markers" — specific C-statistics or NRI not available from abstract.
Main limitation: Sample size unreported; CVAI formula is population-specific and requires external validation outside Chinese cohorts.
Equity implications: Specifically developed for and validated in Chinese adults; needs adaptation/re-validation for South Asian, Southeast Asian, and other ethnic groups where body composition patterns differ.
Evidence Maturity: Revised to Validated (prospective design) but with implementation caveats pending full-text review.
Article 7 — cfDECOR: cfDNA Cell-Type Deconvolution via Chromatin Accessibility
PMID: 42036438 | ⚪ Promising Preliminary | Triage Score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Chromatin accessibility–based cfDNA deconvolution is a genuinely novel analytical approach; complements existing methylation and fragmentomics methods; addresses a real gap in tissue-of-origin inference |
| Clinical Relevance | 3 | Purely computational/methodological at this stage; no clinical cohort validation; indirect relevance to future liquid biopsy accuracy improvement |
| Population Reach | 6 | If validated clinically, liquid biopsy applications span multi-cancer early detection — potentially affecting millions; but current stage is too early to claim this reach |
| Implementation Speed | 3 | Bioinformatics tool; requires ATAC-seq data infrastructure; clinical validation pipeline is years away; regulatory pathway undefined |
| Evidence Strength | 4 | Computational method development; no clinical validation data; sample size not reported; abstract-only; medium classification confidence |
Key quantitative result: Proof-of-concept performance metrics not available from abstract.
Main limitation: No clinical validation; ATAC-seq is not a standard cfDNA workflow; significant implementation barriers before clinical use.
Equity implications: Computational tools can in principle reduce cost of liquid biopsy if they improve signal interpretation without additional wet-lab steps; equity impact is speculative at this stage.
Evidence Maturity: ✅ Confirmed Exploratory.
Article 8 — AI Smartphone Obstetric Ultrasound in Sierra Leone
PMID: 42036650 | 🟡 Underserved Population | Triage Score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | AI-enabled point-of-care ultrasound in LMICs is an active and novel application space; usability study in Sierra Leone is contextually valuable though not technically groundbreaking |
| Clinical Relevance | 6 | Task-shifting of obstetric ultrasound to non-specialist providers addresses a critical maternal health gap in sub-Saharan Africa; usability is a necessary precursor to broader deployment |
| Population Reach | 8 | Sierra Leone has one of the world's highest maternal mortality rates; scale-up potential across LMIC settings could affect tens of millions of pregnancies annually |
| Implementation Speed | 5 | Technology is available; barriers include infrastructure (power, connectivity), training, regulatory approval in-country, and funding; mixed-methods usability data is a prerequisite step |
| Evidence Strength | 4 | Mixed-methods usability study; no diagnostic accuracy or outcome data reported; sample size not stated; abstract-only; medium classification confidence |
Key quantitative result: Qualitative usability findings — no quantitative metrics available from abstract.
Main limitation: No diagnostic accuracy data; usability ≠ efficacy; sample size unknown; generalizability beyond Sierra Leone context requires validation.
Equity implications: Directly targets one of the most underserved populations globally; if scaled, could narrow a stark maternal health equity gap between LMICs and high-income countries.
Evidence Maturity: ✅ Confirmed Exploratory — necessary implementation research step.
Article 9 — Fibroblast Senescence Transcriptomics and Alzheimer's Classification
PMID: 42036745 | ⚪ Promising Preliminary | Triage Score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Linking replicative senescence stages in peripheral fibroblasts to AD-specific transcriptomic signatures is a conceptually novel approach; mid-old senescence window concept adds a temporal dimension to peripheral biomarker discovery |
| Clinical Relevance | 3 | Very early-stage; fibroblast biopsy for AD diagnosis is not clinically practical; the real value is identifying candidate genes that may translate to accessible blood-based markers |
| Population Reach | 7 | Alzheimer's disease affects ~55 million people globally; any advance in accessible early diagnostics has enormous reach if validated |
| Implementation Speed | 2 | Peripheral fibroblast senescence profiling is not near clinical implementation; the identified gene candidates (H2AC18, H1-2, LTBP1) would need blood-based assay development and large-scale validation |
| Evidence Strength | 3 | n=26 (13 AD, 13 controls) is very small; ML classifier accuracy >0.9 on a 26-sample training/test set is subject to severe overfitting concerns; abstract-only |
Key quantitative result: ML classifier >0.9 accuracy (n=26; overfitting risk high); H2AC18, H1-2, LTBP1 correlated with cortical amyloid burden and plasma pTau217.
Main limitation: Critically small n=26; classifier accuracy almost certainly inflated by overfitting; fibroblast culture model adds pre-analytical variability; no independent validation cohort.
Equity implications: If peripheral biomarkers could be translated to simple blood tests, AD diagnostics could become significantly more accessible to underserved populations currently excluded from expensive PET/CSF-based workups.
Evidence Maturity: ✅ Confirmed Exploratory — hypothesis-generating only.
Article 10 — LncRNA PCAT18 in Blood Cancers: Narrative Review
PMID: 42036629 | ⚪ Promising Preliminary | Triage Score: 4
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | PCAT18 has emerging literature but is not widely characterized in hematologic malignancies; the review synthesizes a nascent field with some novelty |
| Clinical Relevance | 2 | Narrative review with no primary clinical data; no validated clinical test or therapy; context-building only |
| Population Reach | 4 | Blood cancers are collectively common (~1.3M new diagnoses/year globally); but PCAT18-targeted therapy is preclinical |
| Implementation Speed | 1 | No clinical translation pathway established; bioavailability and target delivery challenges unresolved |
| Evidence Strength | 3 | Narrative review; no primary data; mixed species models; medium classification confidence |
Evidence Maturity: ✅ Confirmed Exploratory.
Article 11 — ADC Evolution in Breast Cancer: Narrative Review
PMID: 42036664 | ⬜ Standard | Triage Score: 4
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | ADC field evolving rapidly; review in a high-impact journal synthesizes current state including TME immunomodulation angle — useful landscape framing |
| Clinical Relevance | 5 | ADCs (T-DXd, sacituzumab govitecan) are already in clinical use; review contextualizes emerging targets (HER3, TROP-2) and combinations — clinically relevant for oncologists managing breast cancer |
| Population Reach | 7 | Breast cancer is the most common cancer globally (~2.3M new cases/year); ADC-eligible patients represent a large and growing subset |
| Implementation Speed | 4 | Emerging ADC combinations need clinical trial validation; existing approved ADCs already implemented; HER3/TROP-2 agents in late-stage trials |
| Evidence Strength | 3 | Narrative review; no primary data; abstract-only |
Evidence Maturity: ✅ Confirmed Exploratory (as a review article).
Article 12 — TILs in TNBC: Molecular Mechanisms Review
PMID: 42036675 | ⬜ Standard | Triage Score: 4
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | CAF–TIL interactions and spatial TIL distribution are active areas; review synthesizes emerging mechanistic understanding |
| Clinical Relevance | 4 | TIL scoring is used in some TNBC contexts already; mechanistic insights may eventually improve TIL-based treatment selection |
| Population Reach | 6 | TNBC accounts for ~15% of ~2.3M annual breast cancer cases; represents highest unmet need subtype |
| Implementation Speed | 3 | Spatial TIL analysis requires advanced pathology infrastructure; CAF-targeted therapeutics are preclinical |
| Evidence Strength | 3 | Narrative review; no primary data; medium classification confidence |
Evidence Maturity: ✅ Confirmed Exploratory.
Article 13 — MXene-CRISPR/Cas9 Nanoplatform for Cervical Cancer
PMID: 42036673 | ⚪ Promising Preliminary | Triage Score: 4
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Integration of MXene photothermal/photodynamic activity with CRISPR-mediated FABP5 silencing is technically innovative; ROS amplification mechanism is novel |
| Clinical Relevance | 2 | Preclinical only; significant translational barriers for intratumoral delivery of CRISPR nanoplatforms; non-human cap applies (max 5) |
| Population Reach | 5 | Cervical cancer affects ~660,000 women/year globally with high burden in LMICs; but this specific approach is far from clinical use |
| Implementation Speed | 1 | Multiple regulatory, manufacturing, and safety hurdles for CRISPR-based nanoplatform in humans; 10+ year timeline realistic |
| Evidence Strength | 4 | In vitro + xenograft data; ~96% tumor inhibition is striking but xenograft models frequently overestimate clinical efficacy; non-human study cap applies |
Evidence Maturity: ✅ Confirmed Exploratory.
Article 14 — Multidimensional Biomarker System for CKM Syndrome: Systematic Review
PMID: 42036643 | ⬜ Standard | Triage Score: 4
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | CKM syndrome is a recently recognized clinical entity (AHA 2023); multi-omics + AI framework is conceptually current but primarily synthesizes existing approaches |
| Clinical Relevance | 4 | Framework-level contribution; no validated clinical tool proposed with primary data |
| Population Reach | 8 | CKM syndrome encompasses diabetes, CKD, and CVD — collectively affecting >1 billion people globally |
| Implementation Speed | 3 | Multi-omics integration in routine care remains aspirational; dried blood spot/organ-on-chip elements are not near standard clinical deployment |
| Evidence Strength | 3 | Systematic review without primary data; abstract-only; medium classification confidence |
Evidence Maturity: ✅ Confirmed Exploratory.
Article 15 — FGFR3 Axis in CRC Peritoneal Metastasis
PMID: 42032842 | ⚪ Promising Preliminary | Triage Score: 4
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Autologous paired CRC-mesothelial cell model from malignant ascites is methodologically creative; stromal FGFR3 as peritoneal metastasis vulnerability is novel mechanistic insight |
| Clinical Relevance | 3 | Single-patient derivation; preclinical only; non-human cap applies (max 5); FGFR inhibitors (infigratinib, BGJ398) exist clinically but not in this context |
| Population Reach | 5 | CRC peritoneal metastasis affects ~15% of ~1.9M annual CRC cases — meaningful but highly specific subpopulation |
| Implementation Speed | 2 | Requires clinical trial development for FGFR inhibition in peritoneal CRC; at minimum 5–10 years |
| Evidence Strength | 4 | Single-patient autologous model; xenograft validation; PMC full text available; inherently limited by n=1 patient derivation |
Evidence Maturity: ✅ Confirmed Exploratory.
Article 16 — Medical Device Development for Rare/Pediatric Populations: Landscape
PMID: 42036679 | ⬜ Standard | Triage Score: 3
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Policy/landscape overview; no new data or discovery |
| Clinical Relevance | 3 | Indirectly relevant — regulatory advocacy framing; no direct clinical decision support |
| Population Reach | 6 | Rare and pediatric diseases collectively affect millions; systemic change in device innovation policy could have broad long-term impact |
| Implementation Speed | 3 | Regulatory pathway changes require multi-stakeholder consensus and legislative action — slow |
| Evidence Strength | 3 | Narrative landscape review; no primary data; medium classification confidence |
Evidence Maturity: ✅ Confirmed Exploratory.
Article 17 — Dietary Phytochemicals and Epigenetic Regulation in Blood Cancers
PMID: 42033074 | ⬜ Standard | Triage Score: 3
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Curcumin/resveratrol epigenetic effects in cancer are extensively reviewed; little novel synthesis beyond prior reviews |
| Clinical Relevance | 2 | No validated clinical interventions; bioavailability limitations unresolved; mixed preclinical/clinical evidence base |
| Population Reach | 5 | Blood cancers affect ~1.3M/year globally; dietary interventions would theoretically apply broadly but lack evidence |
| Implementation Speed | 2 | No clinical validation pipeline; bioavailability issues unresolved |
| Evidence Strength | 2 | Critical review with no primary data; mixed species models; medium classification confidence |
Evidence Maturity: ✅ Confirmed Exploratory.
PHASE 3 — Ranking
Conflict Check
No major conflicting findings across articles in this batch. Articles 5 and 6 are complementary rather than conflicting on cardiometabolic risk stratification in Chinese populations. Article 2 (TMB in HNSCC) aligns with the broader precision oncology literature without internal contradiction.
Composite Impact Score Table
Weighting: Clinical Relevance 30% | Population Reach 25% | Scientific Novelty 20% | Implementation Speed 15% | Evidence Strength 10%
| Rank | Article | Flag | Triage Score | Clinical Rel. (×0.30) | Pop. Reach (×0.25) | Sci. Novelty (×0.20) | Impl. Speed (×0.15) | Evid. Strength (×0.10) | Composite | Study Design |
|---|---|---|---|---|---|---|---|---|---|---|
| 🥇 1 | ZUMA-2 5-yr: Brexu-cel in R/R MCL (PMID 42036693) | 🟠 | 9 | 9 (2.70) | 5 (1.25) | 7 (1.40) | 8 (1.20) | 7 (0.70) | 7.25 | Pivotal trial follow-up |
| 🥈 2 | TMB Predicts PD-1 Response in HNSCC (PMID 42036313) | 🟢 | 7 | 8 (2.40) | 6 (1.50) | 6 (1.20) | 7 (1.05) | 8 (0.80) | 6.95 | Systematic review/meta-analysis |
| 🥉 3 | Allostatic Load & CRC Risk, Asian Cohort (PMID 42033061) | 🟡 | 6 | 5 (1.50) | 8 (2.00) | 6 (1.20) | 5 (0.75) | 7 (0.70) | 6.15 | Prospective cohort |
| 4 | MM SES Disparities, Australia (PMID 42032835) | 🟡 | 6 | 6 (1.80) | 5 (1.25) | 5 (1.00) | 6 (0.90) | 7 (0.70) | 5.65 | Registry cohort |
| 5 | AI Smartphone Ultrasound, Sierra Leone (PMID 42036650) | 🟡 | 5 | 6 (1.80) | 8 (2.00) | 5 (1.00) | 5 (0.75) | 4 (0.40) | 5.95 | Mixed-methods |
| 6 | LDL-C + CVAI Cardiometabolic Risk Tool (PMID 42036685) | ⬜ | 5 | 6 (1.80) | 7 (1.75) | 5 (1.00) | 6 (0.90) | 5 (0.50) | 5.95 | Prospective cohort |
| 7 | MetSyn Trajectory & Cardiometabolic MM (PMID 42036722) | ⬜ | 5 | 5 (1.50) | 7 (1.75) | 5 (1.00) | 4 (0.60) | 5 (0.50) | 5.35 | Longitudinal cohort |
| 8 | cfDECOR: cfDNA Deconvolution Tool (PMID 42036438) | ⚪ | 5 | 3 (0.90) | 6 (1.50) | 7 (1.40) | 3 (0.45) | 4 (0.40) | 4.65 | Computational method |
| 9 | Fibroblast Senescence & AD Classification (PMID 42036745) | ⚪ | 5 | 3 (0.90) | 7 (1.75) | 7 (1.40) | 2 (0.30) | 3 (0.30) | 4.65 | Experimental/ML |
| 10 | ADC Evolution in Breast Cancer (Review) (PMID 42036664) | ⬜ | 4 | 5 (1.50) | 7 (1.75) | 5 (1.00) | 4 (0.60) | 3 (0.30) | 5.15 | Narrative review |
| 11 | FGFR3 in CRC Peritoneal Metastasis (PMID 42032842) | ⚪ | 4 | 3 (0.90) | 5 (1.25) | 7 (1.40) | 2 (0.30) | 4 (0.40) | 4.25 | Preclinical |
| 12 | TILs in TNBC (Review) (PMID 42036675) | ⬜ | 4 | 4 (1.20) | 6 (1.50) | 5 (1.00) | 3 (0.45) | 3 (0.30) | 4.45 | Narrative review |
| 13 | MXene-CRISPR for Cervical Cancer (PMID 42036673) | ⚪ | 4 | 2 (0.60) | 5 (1.25) | 7 (1.40) | 1 (0.15) | 4 (0.40) | 3.80 | Preclinical |
| 14 | CKM Syndrome Biomarker Framework (PMID 42036643) | ⬜ | 4 | 4 (1.20) | 8 (2.00) | 5 (1.00) | 3 (0.45) | 3 (0.30) | 4.95 | Systematic review |
| 15 | LncRNA PCAT18 in Blood Cancers (PMID 42036629) | ⚪ | 4 | 2 (0.60) | 4 (1.00) | 5 (1.00) | 1 (0.15) | 3 (0.30) | 3.05 | Narrative review |
| 16 | Rare/Pediatric Medical Device Landscape (PMID 42036679) | ⬜ | 3 | 3 (0.90) | 6 (1.50) | 3 (0.60) | 3 (0.45) | 3 (0.30) | 3.75 | Landscape review |
| 17 | Dietary Phytochemicals & Epigenetics in Blood Cancer (PMID 42033074) | ⬜ | 3 | 2 (0.60) | 5 (1.25) | 3 (0.60) | 2 (0.30) | 2 (0.20) | 2.95 | Critical review |
| — | PMID 42035021 | ⬜ | — | — | — | — | — | — | Deferred | Unknown |
Tie-break note (Ranks 5 & 6): Articles 5 and 6 score identically at 5.95. Tie broken by Clinical Relevance: both score 6. Secondary tie-break on Evidence Strength: Article 6 (prospective registry cohort) scores 5; Article 5 (mixed-methods usability) scores 4. Article 6 ranks ahead on Evidence Strength. However, in final presentation I keep Article 5 slightly ahead given its population equity weight and UNDERSERVED_POPULATION flag — the formula tiebreak is overridden by the equity flag rule per Phase 3 priority flag guidance.
Rank Justification Summaries
🥇 Rank 1 — ZUMA-2 Five-Year Follow-Up (42036693) The only five-year durability dataset for the only approved CAR-T therapy in mantle cell lymphoma, a disease where median survival post-relapse historically measured in months. With a median OS of 46.5 months and 60.2 months in complete responders — and no new safety signals including no T-cell malignancies — this is directly practice-reinforcing evidence. Brexucabtagene autoleucel (Tecartus) is already approved; these data cement its role and are immediately usable in patient counseling, treatment protocols, and health technology assessments. The single-arm design is the main constraint, but in this rare refractory disease setting, a comparator-free pivotal extension is accepted standard. Evidence Strength of 7 meets the threshold for Rank 1 eligibility. Why it matters: Patients with relapsed MCL now have credible evidence of multi-year survival from a single treatment course — a transformation from what was one of the most dire lymphoma prognoses.
🥈 Rank 2 — TMB Meta-Analysis in HNSCC (42036313) This meta-analysis of 17 cohorts fills a specific and clinically pressing gap: which HNSCC patients should receive PD-1 blockade? With a 2.8-fold improved response rate and 42% OS benefit in high-TMB patients, and near-zero statistical heterogeneity (I²=0%) for ORR, this is one of the cleanest biomarker meta-analytic signals in recent oncology literature. The calibration of bTMB (≥16 mut/Mb) vs. tTMB (~10 mut/Mb) thresholds is directly actionable for labs implementing liquid biopsy testing. Why it matters: A validated, accessible biomarker that identifies HNSCC patients most likely to respond to immunotherapy could prevent both under-treatment of responders and toxicity in non-responders.
🥉 Rank 3 — Allostatic Load & CRC Risk in Asian Cohort (42033061) In 30,443 participants with 7+ years of follow-up, high allostatic load conferred a 53% elevation in colorectal cancer risk — a finding that extends a promising Western construct to the most populous and understudied demographic in global cancer research. This is a prospective, registry-linked, full-text study, not a hypothesis. The composite nature of allostatic load (reflecting cumulative physiological stress across multiple systems) gives it potential as a scalable risk stratification input across diverse Asian health systems. Why it matters: A single composite score — calculable from routine clinical data — may identify high-risk individuals for intensified CRC screening before symptoms appear.
Rank 4 — MM SES Disparities, Australia (42032835) Rigorous quantification of ASCT access as the mediating mechanism between SES and MM survival creates a direct, actionable policy lever. Why it matters: Closing the gap in ASCT referral for lower-SES myeloma patients could eliminate most of the observed 27% excess mortality difference — no new drugs required.
Rank 5 — AI Smartphone Ultrasound, Sierra Leone (42036650) Usability validation is a necessary but insufficient step toward deployment; ranks high on population reach and equity significance. Why it matters: Task-shifting obstetric ultrasound to community health workers in Sierra Leone — one of the world's highest maternal mortality settings — represents a scalable maternal health equity intervention if diagnostic accuracy is confirmed.